Introduction {#sec0001}
============

Among abundant Chinese Traditional Medicine (TCM), Radix Bupleuri (RB) is the dry root of *Bupleurum chinense* DC. (Apiaceae) and *Bupleurum scorzoneri-folium* Willd according to *Chinese Pharmacopoeia* and is produced in the regions of China (mainly in the province of Liaoning, Jilin, Henan, Hebei, Jiangsu and Anhui) and other Asian countries (like Japan and Korea) ([@bib0070]). Meanwhile, some other *Bupleurum* species, such as *Bupleurum falcatum* L. and *Bupleurum yinchowense* are also recorded in some *Japanese Pharmacopeia* and have been applied in Eurasia and North Africa ([@bib0047], [@bib0096]). As one of the most widely used herbal treatments, RB is first recorded in *Shen Nong Ben Cao Jing*, the earliest monograph concerning TCM ([@bib0071]), and has been clinically practiced for over past 2000 years to treat fever, chill, tumor, hypochondria, inflammation and uterine prolapsed ([@bib0008], [@bib0072], [@bib0089]). Recently, RB has been used as a hepatoprotective herb to treat various liver diseases, such as chronic hepatic inflammation, viral hepatitis and even hepatocellular carcinoma in patients with the complication of liver cirrhosis ([@bib0038], [@bib0103], [@bib0162]). Clinically, several patented TCMs or traditional Chinese prescriptions made from or containing RB are widely available in China, including *Chai-Hu-Shu-Gan* tablets, *Xiao-Yao-Wan* tablets, *Xiao-Chai-Hu-Tang, Da-Chai-Hu-Tang* and *Chai-Hu-Shu-Gan-San* ([@bib0020]). Chinese pharmacopoeia provides the suggested clinical safe dosage of RB in prescriptions, ranging from 3 to 10  g/day (based on 70  kg body weight) ([@bib0070]).

Several types of plant secondary metabolites extracted and isolated from *Bupleurum* species, including triterpenoid saponins (saikosaponins), steroidal saponins, flavonoids, coumarins, fatty acids, essential oils, polyacetylenes and polysaccharides, have been identified ([@bib0078], [@bib0080]). Previous phytochemical/analytical studies investigated the basis of different aglycones among Bupleurum species and categorized SSs into seven different types ([@bib0079], [@bib0104]). Structures of SSs are showed in [Fig. 1](#fig0001){ref-type="fig"} . Epoxy-ether oleanane type SSa, SSc and SSd have been identified in most triterpenoid saponins, and other SSs with different aglycone or sugar chains, like SSb1, SSb2, SSb3 and SSb4, are also found in various Bupleurum species ([@bib0007]). Over 100 different glycosylated oleanane-type and ursane-type saponins were isolated from the roots of different *Bupleurum* species. Although these isolated SSs are varied in the abundance among different plants from different origins, oleanane-type SSa, SSb, SSc and SSd have been isolated and identified in almost all *Bupleurum* species ([@bib0041], [@bib0082]). Saikosaponins (SSs) are major bioactive compounds in RB, which have been characterized with anti-inflammatory, anti-tumor, anti-viral and hepatoprotective activity both *in vivo* and *in vitro* ([@bib0006], [@bib0107]). Anti-depressive, anti-neurodegeneration and nephroprotective effects of SSs have also drawn great attention recently. Meanwhile, lack of systematic pharmacokinetics study, inconsistent dosage used in different studies, contradictory experimental evidence and potential risk of hepatotoxicity induced by overdose have become significant obscure for the development of SSs based therapy. These issues have been long neglected by previous studies and reviews and a comprehensive review with perspectives on the limitations of current pharmacology and toxicology researches of SSs is still missing.Fig. 1Structures of SSs. Glu, glucose; Fuc, Fucose; Rham, Rhamnose.Fig 1

In this review, we will focus on the extraction, quality control, biosynthesis, pharmacological/toxic effects and metabolism of SSs. This review will provide a comprehensive understanding of recent studies, highlight shortcomings of previous studies and encourage a wider pre-clinical evaluation and clinical application of SSs and derivatives in the immediate future.

Methods {#sec0002}
=======

This study is based on search of online academic databases (including PubMed, Google Scholar, Web of Science and CNKI) using search terms of "Saikosaponin", "Radix Bupleuri", "Bupleurum" and their combinations. 354 papers were found and 165 papers primarily from 2003 to 2018, regarding to extraction, purification, identification, biosynthesis, pharmacology and toxicology, are included, categorized by topics and summarized. Critical previous studies before 2003 were also reviewed to provide essential background information. Case reports, several review articles and papers regarding to agriculture, economy, and basic phytology were excluded.

Extraction and identification of SSs {#sec0003}
====================================

In TCM, raw herbs processing has been documented in the *Huang Di Nei Jing* for 2000 years and is essential before use. Different TCM processing of same herb may results in different pharmacological effects of final herbal extracts and TCM formulas. Vinegar baking is a common method for RB processing by soaking in rice vinegar and baking until dry, according to China pharmacopoeia ([@bib0018]). Vinegar baked RB (VBRB) is predominantly used for the treatment of liver diseases and has been reported to possess higher potency and lower toxicity than raw RB ([@bib0074], [@bib0125], [@bib0146], [@bib0170]). Several studies suggested that vinegar baking switches SSs composition in the RB extract, from higher contents of SSa, SSc and SSd in raw RB extract to higher contents of SSb1 and SSb2 in VBRB extract ([@bib0074]). Different RB processing methods contribute to the different composition of SSs and yield of individual SS monomers.

Conventionally, some traditional extraction processes, including heat-reflux extraction, ultrasonic-assisted extraction and solvent-partitioning extraction, were applied to extract SSs from raw RB or VBRB ([@bib0055], [@bib0087], [@bib0088], [@bib0169]). However, most of these methods are accompanied with disadvantages as time-consuming or wastage of organic solvents. Recently, Li et al. employed accelerated solvent extraction (ASE)-based method to extract SSs from the dry roots of *Bupleurum falcatum* and reported that ASE method was more effective and faster under specific conditions, compared with previous traditional methods ([@bib0069]). Supercritical fluid extraction using CO~2~ as solvent was also optimized to extract SSs from RB at lower temperature and with lower trace of organic solvent contamination ([@bib0118]).

Isolation and purification of SS monomers from SS extracts are principally performed by solid-based chromatography methods or solvent partition coupled with preparative liquid chromatography, which are time consuming and with low recovery rate. Due to the lack of chromophores in most SSs, it was limited to detect and identify only a few of SSs using high performance liquid chromatography (HPLC) method with standard ultraviolet (UV) detector in the past decades. Previous findings suggested that evaporative light scattering detection (ELSD), instead of UV detection, has the potential to become a valuable alternative method for the identification of SSs ([@bib0123]). More recently, a charged aerosol detection method, which had been developed to improve the sensitivity and reproducibility of ELSD ([@bib0128]), displayed a higher sensitivity to the analysis of SSs ([@bib0026]). Several studies have established a fast resolution liquid chromatography coupled with ELSD method and successfully separated multi-samples in RB from different source ([@bib0040]). Based on these investigations, in 2010, a rapid and improved HPLC-ELSD method was also established to evaluate the quality of SSs, which confirmed three major constituents SSa, SSc and SSd and simultaneously detected ten different SSs in RB extract ([@bib0061]). A recent study further optimized one of the countercurrent separation techniques, centrifugal partition chromatography, coupled with HPLC-ELSD method to efficiently obtain purified SSa and SSc from modified two-phase solvent system-derived SSs enriched RB extract ([@bib0157]).

Compared to HPLC, HPLC coupled with mass spectrometer (HPLC-MS) is another analysis method with superior sensitivity and selectivity, and significantly improves detection and identification of SSs in biological samples, which is critical for pharmacokinetics studies of SSs. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was employed to simultaneously detect the contents of SSs (SSa, SSc and SSb2) in rat plasma ([@bib0148]). Most recently, both SSa and SSd, as well as 15 and 16 metabolites, respectively, were simultaneously identified in various bio-samples, including plasma, bile, feces and urines, by using state-of-the-art liquid chromatography-diode array detector coupled with hybrid ion trap-time-of-flight mass spectrometry (LC-DAD-IT-TOF-MS) analysis ([@bib0084], [@bib0160]).

Biosynthesis of SSs {#sec0004}
===================

Wild RB in nature is too rare to be sufficient for resource exploitation and SSs extraction; and even worse, the supply of cultivated RB falls short of the widespread demand ([@bib0109]). Hence, in addition to agricultural optimization of cultivation conditions ([@bib0031], [@bib0119], [@bib0136]), it become more critical to define the specific pathways and identify key synthases in the biosynthetic process to further improve SSs production and increase SSs contents in RB by gene manipulation. Identification and characterization of key genes involved in the putative biosynthetic pathways of SSs in Bupleurum have been well-summarized previously ([@bib0080]). Briefly, SSs are biosynthesized via mevalonate-dependent isoprenoid pathways from a common precursor, 2,3-oxidosqualene ([@bib0002]), which is cyclized to β-amyrin and to cycloartenol by different oxidosqualene cyclases (OSCs), named as β-amyrin synthase (BAS) and cycloartenol synthase (CAS) in higher plants ([@bib0035]). Then, β-amyrin undergoes a set of cytochrome P450-dependent (P450)-induced oxidations/hydroxylations and glycosyl transfer reactions catalyzed by uridine diphosphate-glycosyltransferases ([@bib0035], [@bib0079]), which are encoded by multigene assigned from *Lotus japonicus* L ([@bib0111]), *M. truncatula* ([@bib0067]), A. *thaliana* and rice genomes ([@bib0100]). Meanwhile, plant hormone methyl jasmonate has been reported to regulate the accumulation of related secondary plant metabolites ([@bib0033]) and promote SSs production via increasing the transcript encoding of P450 hydroxylases ([@bib0005], [@bib0115]). Recent studies also found that 2,3-oxidosqualene, the intermediate product in first committed biosynthesis step of SSs, could be yielded through several established processes, from two molecules of acetyl-CoA, 3‑hydroxy‑3-methylglutaryl-CoA (HMG-CoA), mevalonic acid, 5-phosphomevalonate, farnesyl pyrophosphate, and finally into squalene ([@bib0056], [@bib0114]). Overexpression or upregulation of these critical enzymes involved in these key steps of biosynthesis, especially for OSC, P450 and uridine diphosphate-glycosyltransferases, are not only essential for increasing the yield and speed of SSs biosynthesis, but also for controlling the quality of SSs production.

Pharmacological effects of SSs {#sec0005}
==============================

Emerging evidence suggested that SSs, as major bioactive compounds in RB, have various pharmacological effects, including anti-inflammatory, immunoregulatory, anti-cancer, anti-oxidative stress effects. Summary of these pharmacological effects, *in vitro* and *in vivo* research models, dosages and concentrations of individual SSs are listed as [Table 1](#tbl0001){ref-type="table"} . Meanwhile, vital targets and putative pathways involved in various bioactivities of SSs are summarized in [Fig. 2](#fig0002){ref-type="fig"} .Table 1Pharmacological effects of SS with detailed information.Table 1**CompoundAnimal/Cell (organ)Model/stimulationDosageTimeEffectsRefAnti-inflammation**SSaRAW 264.7 cellsLPS3.125 -- 12.5 μM5 or 20 hCOX-2, iNOS, TNF-α, IL-1β, IL-6, NF-κB, IκBα and MAPK↓, IL-10 ↑([@bib0174])SSaOsteoarthritis chondrocytesIL-1β5 -- 15 μM12 hPGE2, MMP-1, MMP-13 and NF-κB activation([@bib0032])SSaHUVEC cell lineLPS3, 6, 12 μM12 hCOX-2 and iNOS, NF-κB activation, TLR4 migration ↓([@bib0030])SSaMale BALB/c miceLPS-induced lung injury5 -- 20  mg/kg12 hMPO activity, TNF-α and IL-1β, NF-κB and NLRP3 activation ↓([@bib0025])SSaSD ratCCI-induced TBI20  mg/kg7 dayneuron inflammation, MMP-9, MAPK, c-JNK, TNF-α, IL-6, ↓([@bib0099])SSaSD ratCCl~4~-induced liver injury(0.004% SSs)8 weekTNF-α, IL-1β, and IL-6, TGF-β1 and Hydroxyproline ↓([@bib0142])SSa, dRAW 264.7 cellsLPSSSa, 12.5  μM; SSd, 50 μM24 hLPS-induced iNOS, COX-2, NO, PGE2, TNF-α, IL-6 and NF-κB ↓([@bib0090])SD ratsCarrageenan-induced paw edemaSSa 5 -- 20  mg/kg; SSd 5 -- 20  mg/kg1 -- 6 hAcute inflammation ↓, paw thickness ↓BALB/c miceAcetic acid1 hAcute inflammation ↓, permeability ↓SSdC57BL6 miceAPAP-induced liver injury2  mg/kg/day5 dayAPAP-induced NF-kB, STAT3, Il6 and Ccl2↓, IL-10 ↑([@bib0083])SS mixtureKunming miceFormalin-induced paw edma0.52 -- 4.68  g/kg3 dayAA and PGE2 production ↓([@bib0095])SSa, b1, dC6 rat glioma cellN/A50 μM10 minStimulate PGE2 release([@bib0059])SGdC6 rat glioma cellCa^2 + ^ionophore A23187-/histamine-induced PGE2 production1-- 20 μMN/ANo effects on basal level PGE2 production from AA.([@bib0057])Ca^2 + ^ionophore-/histamine-induced PGE2 production ↓SSaWistar ratsCLP-induced experimental spesis1.0 -- 5.0  mg/kg8 hCLP-induced TNF-α, IL-6, NOD2 mRNA expression and phospho-NF-κB p65 ↓([@bib0167])SSaBone marrow cells, RAW264.7RANKL-induced osteoclastogenesis50 μM24 -- 72 hosteoclast differentiation, NFATc1, c-fos, MAPK, JNK and NF-κB activation ↓([@bib0172])SSsHUVEC cell lineOx-LDL10 -- 40 μM24  h, 48 hInflammatory cytokines ↓, p-38, ERK, JNK and NF-κB activation ↓([@bib0153])**Immune regulation**SS mixtureMiceConcanavalin A (ConA)N/A8 h/24 hCD4 + /CD8^+^ T cells ratio ↑, IL-18 ↑, IL-10 ↓([@bib0149])SSa, b2, dMouse splenocytesConA0.5 -- 2.5  μg/ml48 hProliferation ↑, IFN-γ, TNF-α ↓, IL-4, IL-10 ↑([@bib0132])SSaMouse lymph node cell isolatedConA1 -- 10 μM72 hCon A-stimulated IL-2, IFN-γ and TNF-α production ↓, G0/G1 arrest([@bib0117])SSdMouse spleenic T cellsConA, anti-CD3 mAb, A231871 -- 10  μg/ml1 -- 5 daysIL-2 production and IL-2 receptor expression, c-fos gene transcription ↑([@bib0051])SSdMouse lymphocytes from lymph nodesConA, and PMA5, 10 and 20 μM12 hIL-2 production, CD69 and CD71 expressions of mouse T cells, phosphorylations of IκBα and JNK ↓, interfered with PKCθ translocation([@bib0063])SSdMouse myocytesAnti-CD3mAb, PMA, A231873  μg/ml1 -- 6 dayConstitutive DNA synthesis ↓, growth response and IL-2/IL-4 production ↑([@bib0050])SSdMouse T lymphocytesConA, and PMA5 -- 15 μM30 to 180 minT cell activation, NF-kB, IKK and Akt activities, DNA binding activity, the nuclear translocation of NF-AT and AP-1, and production of IL-6, TNF-α and IFN-γ ↓([@bib0139])SSdWistar ratsAnti-Thy1 mAb 1--22--3-induced rat model of glomerulonephritis0.6 or 1.8  mg/kg31 dayUrinary protein and systolic blood pressure, ECM, crescentic formation, infiltration of macrophages and CD8^+^T lymphocytes, TGF-β1 and type I collagen in the kidneys ↓([@bib0068])SSdPBMCsMonocytes derived dendritic cells5, 10 and 20 μM5 daysDifferentiation of DCs, CD1a, CD80, CD86↓, CD14, CD32, CD86 .etc ↑([@bib0156])SSaWistar RatPassive cutaneous anaphylaxis1 -- 10  mg/kgN/Acutaneous dyeexudation ↓([@bib0105])Guinea pig tracheaHistamine, leukotriene D4100 -- 500  μg/ml10 minTrachea contraction ↓Peritoneal mast cellsCompound 48/80, A23187100 -- 500 μg/mlN/AHistamine releases ↓SSaMale micePCA (Compound 48/80)0.1 -- 0 .5 mg/kgN/APCA, ast cells degranulation, Ca^2 + ^mobilization ↓([@bib0133])Mast cells (human LAD2 cells)0.1 -- 0.5 μM1hSSdRat basophilic leukemia-2H3 cellβ-Conglycinin50  ng/ml0.25 -- 1hCell degranulation, ROS, Ca^2+^mobilization ↓([@bib0034])SSbHEK293 cell/ Mast cellsIgE2.5 -- 10 μMN/ASSb activates TAS2R14 with EC50 4.9 μM, mast cells degranulation ↓([@bib0166])**Anti-viral activity**SSaA549 cells (lung)Influenza A Virus3.8 to 7.6 μM8 to 72 hReplication of influenza A virus strains, NF-κB and caspase 3-dependent virus ribonucleoprotein nuclear export, pro-inflammatory cytokine production ↓([@bib0013])SSa, b2Human fetal lung fibroblastsHuman coronavirus 229E infection0.25 -- 25 μM8 hViral attachment and penetration ↓, SSb2 IC50 1.7 μM([@bib0021])SSdVero cellsmeasles and herpes simplex virus5 mM24 hdirect inactivating effects on both measles and herpes simplex virus([@bib0127])SScHuman hepatoma cellsHBV6 hHBV DNA replication ↓([@bib0023])SSb2Human hepatoma HuH7 cells, HuH7.5 and S29 cellsHCV50 μM7 dayNeutralization of virus particles, viral attachment, viral entry/fusion, binding of serum-derived HCV onto hepatoma cells ↓([@bib0077])**Anti-oxidative and anti-apoptotic effects**SSaSD ratCCl4(0.004%, SSs)8 weekoxidative stress ↓([@bib0142])SSdHepatoma cell line (CRL-1548)CCl42  μg/ml48 hcollagen I deposition in the liver, serum alanine aminotransferase, liverTGF-beta1 ↓([@bib0024])SD ratsCCl41.8  mg/kg4 weekSSdHL7702 cells (liver)CCl40.5 -- 2 μM24 hMDA, TSOD, oxidative stress, inflammation ↓([@bib0076])SSdLLC-PK1 cells (kidney)Heat stress1 or 3  μg/ml10 hMDA, cellular damage ↓, the activity of SOD, CAT, and GPx, the expression of copper and zinc SOD-1, CAT, GPx-1 and HSP72 ↑([@bib0165])SSdNRK-52E cells (kidney)High Glucose15 -- 90 μM24 -- 48 hProliferation, ROS, MDA and SOD activity ↓, MnSOD and SIRT3 expression ↑([@bib0168])SSdHK-2 cells (kidney)Cisplatin20 -- 150 μM24 hViability rate ↑, attenuated the caspase-3 activation and programmed apoptosis, TNF-α, IL-1β, IL-6, iNOS, DDP-induced activation of NF-κB, JNK, and MAPKs ↓([@bib0094])SSdPC12 cells (nerve system)H~2~O~2~50 - 600  μg/ml24 hApoptosis rate, caspase-3 activation, PARP cleavage, MDA, lactate dehydrogenase ↓, activity of SOD, total antioxidant capacity ↑([@bib0152])SSdSH-SY5Y cells (nerve system)MPP+15 -- 60 μM24 hcell viability ↑, oxidative stress, apoptotic cell deaths and caspase-3 activity↓([@bib0078])SSdSprague-Dawley ratsVentilator-induced lung injury60 minPulmonary neutrophil infiltration, MPO, MIP-2, IL-6 and TNF-α ↓, TGF-β1 and IL-10 ↑([@bib0131])SSa, dHeLa and Siha cells, A549 cells, or SKOV3 cells (cancer cells)N/ASSa, 10  μM, SSd, 2 μM48 hcancer cells death, ROS accumulation ↑([@bib0134])**Anti-cancer effects**SSa, dA549, HepG2, Hep3B, Bcap-37, MCF-7N/ASSa, 8 -- 20  μM\
SSd, 5 -- 30 μM48 hCell growth ↓([@bib0065])SSaHuman colon carcinoma cellsN/A20 μM15 hER stress, apoptosis, colony inhibition, caspase-3, −8, and −2 ↑([@bib0049])SSaHuman colon carcinoma cellsN/A20 μM5 -- 15 hActivities of caspase-4, 2 and 8, Bid cleavage, and activation of Bax ↑([@bib0054])SSaHuman breast cancer cell linesN/A5  µg/ml4 -- 48 hProliferation or viability of cancer cells ↓, sub-G1 population of cell cycles ↑([@bib0014])SSaHepatoma cell line HepG2N/A10 μM6 -- 24 hHepG2 growth ↓([@bib0143])SSb2B16 melanoma cellsN/A20 μM48 hG1 phase accumulation, apoptosis induction ↑([@bib0176])N/A5 mM30 dayDifferentiation of B16 melanoma cells ↑([@bib0175])SSdSMMC-7721 and HepGN/A2.5 -- 15  μg/ml24 -- 72 hHIF-1α, COX-2 ↓([@bib0036])SSdA549N/A1 -- 20 μM6 -- 72 hp53, p21, cell cycle arrest, FasL pathway ↑([@bib0039]b)SSdHepG2 and Hep3B cellsN/A1 -- 10 μM6 -- 48 hCell cycle at G1 phase, cell survival↓, NF-κB pathway ↓([@bib0039]a)SSdDU145 human prostate cancer cellsN/A1 -- 50 μM24 hProliferation of DU145 cells ↓,, caspase-3, p53 and p21 ↑, mitochondrial membrane potential ↓, release of cytochrome c, apoptosis and cell cycle arrest at G0/G1 phase ↑([@bib0154])SSdThyroid cancers cell lines ARO, 8305C and SW1736N/A5 -- 20 μM12 -- 48 hCell apoptosis, G1-phase cell cycle arrest, expression of p53 and bax, p21 ↑, the expression of Bcl-2, CDK2 and cyclin D1 ↓([@bib0086])SSdColon cancer cells HT-29N/A10  μg/ml24 hApoptosis of HT29 ↑, TRAIL, TRAIL-R and caspase10 and/or caspase8 ↑([@bib0091])SSdChemoresistent ovarain cancer cell linesCisplatin0.5 -- 5 μM24 hSensitizes OVCA cells to cisplatin in p52-independent pathway, mitochondrial fragmentation, Ca^2 + ^flux, G2/M cell cycle arrest ↑, mitosis ↓([@bib0124])SSdSMMC-7721Radiation3  μg/ml8 hPotentiates the effects of radiation on SMMC-7721 cells to induce G0/G1 arrest([@bib0129])SSdSMMC-7721 and HepG2Radiation3  μg/ml8 hRadiosensitivity of hepatoma cells, p53 and Bax ↑, Bcl-2, HIF-1α ↓([@bib0130])SSa, dHeLa and Siha, SKOV3, and A549CisplatinSSa, 10  μM, SSd, 2 μM48 hSensitize cancer cells to cisplatin-induced cell death, ROS accumulation ↑([@bib0134])SSdDU145 and CWR22Rv1 cellsN/A10 μM24 hCell growth, colony formation, self-renewal ability of cancer stem cell phenotypes ↓([@bib0171])SSdHeLa and MCF-7 cellsN/A10 μM24 hcytosolic calcium level, autophagy induction, disruption of calcium homeostasis ↑([@bib0137])SSdSD ratsDEN0.03% SSd16 weekHCC development, syndecan-2, MMP-2, MMP-13 and TIMP-2 tissue ↓([@bib0046])SSdSD ratsDEN2  mg/kg1 -- 7 dayDEN-induced hepatocarcinogenesis in rats, C/EBPβ and COX-2 ↓([@bib0092])SSaMCF-7/ADR and HepG2/ADM cellsDoxorubicin, vincristine and paclitaxel5 μM24 -- 48 hApoptosis, retention, chemosensitivity of P-gp overexpressing HepG2/ADM and MCF-7/ADR cells to DOX, VCR and paclitaxel ↑([@bib0155])SSdMCF-7/ADR cellsADR1 -- 5  μg/ml24 -- 48 hSensitivity to ADR ↑, P-gp-mediated efflux ↓([@bib0064])SSdMCF-7/ADR cells and xenograftsDoxorubicin0.5  μg/ml48 hReverse MDR *in vitro* and *in vivo*, doxorubicin metabolism change, xenografts growth sensitive to doxorubicin([@bib0066])**Effects on CNS system**SSaWistar ratsChronic unpredictable mild stress25, 50 or 100  mg/kg4 weekPerimenopausal depression-like symptoms ↓, sucrose preference↑, latency to feed in the novelty-suppressed feeding test, immobility time in the forced swimming test ↓([@bib0019])SSdSD ratsChronic unpredictable mild stress0.75, 1.50  mg/kg21 daySerum corticosterone levels ↓, BDNF, generation of neurons, GR expression and nuclear translocation ↑([@bib0070])SSaHippocampal neuronal culture modelsAcquired epilepsy and status epilepticus0.1 -- 4 μM24 hTerminates SREDs in the HNC model of AE, reduced the peak amplitude of NMDA-evoked current and the peak current amplitude of I(NaP)([@bib0161])SSaCA1 neurons of rat hippocampal slices4AP seizure model1 μM30 minEpileptiform discharges frequency and duration in hippocampal CA1 neurons ↓([@bib0145])SSaSD ratsChronic constriction injury (CCI)6.25 -- 25  mg/kg1 -- 14 dayCCI-induced inflammation, MAPK and NF-κB pathway, neuropathic pain ↓([@bib0173])SSaSD ratCCI-induced TBI20  mg/kg7 dayBody weight loss, AQP-4, MMP-9, MAPK, c-JNK, TNF-α, IL-6, brain edema and blood brain barrier permeability after CCI ↓([@bib0099])SSaSD ratsN/A0.25 -- 1.0  mg/kg1 hMorphine-reinforced behavior ↓([@bib0158])SSaSardinian alcohol-preferring (sP) ratsN/A0.25 -- 1 mg/kg1 hLever-responding for alcohol, amount of self-administered alcohol, and breakpoint for alcohol ↓, GABAB receptors related([@bib0097])SSdPC12 cellsCorticosterone0.125 -- 2  µg/ml24 hTranslocation of the GR to the mitochondria, expression of pro-apoptotic-related signaling events ↓, up-regulating anti-apoptotic-related signaling events ↑([@bib0071])SScSH-SY5Y cells, mouse cortical neurons, PC12 cellsN/A3 -- 10 μM36 hRelease of both Aβ peptides 1--40 and 1--42, tau phosphorylation ↓, NGF-mediated neurite outgrowth, assembly of MT, synaptic marker proteins ↑([@bib0062])**Other effects**SSaHSC-T6 and LX-2 cellsN/A10 μM24 hThe translocation of BAX and BAK from the cytosol to the outer membrane ↑, membrane potential ↓, release of apoptotic factors ↑([@bib0012])SSdHSC-T6 and LX-2 cellsN/A1  μM72 hElicited cell death may occur through caspase-3-dependent, caspase-3-independent and mitochondrial pathways([@bib0017])SSaHSC-T6 cellN/A10 μM72 hERK1/2, PDGFR1 and TGF-β1R, α-sma, TGF-β1, CTGF, p-p38 and p-ERK1/2 ↓, PDGF-BB and TGF-β1-induced cell proliferation and migration ↓([@bib0015])SSd1 μMSSaLX-2 cellsN/A5 μM2, 4 dayBMP-4 expression, hepatic stellate cell activation ↓([@bib0137])SSdHSC-T6 cellN/A5 μM24 hECM deposition, TGF-β1, hydroxyproline, collagen-1 and tissue inhibitor of metalloproteinases-1 ↓, matrix metalloproteinase-1 ↑([@bib0110])Fig. 2Putative pathways involved in SSs bioactivities. GR (Glucocorticoid receptor), P-gp (P-glycoprotein).Fig 2

Effects of SSs on inflammation {#sec0006}
------------------------------

According to the TCM records, RB extracts or isolated components (mainly SSs) have been widely used to relieve inflammatory diseases, such as fever, flu and hepatitis. SSs have also attracted considerable attention because of its significant anti-inflammatory activity. Direct inhibition of pro-inflammatory cytokines expression and regulation of inflammatory mediators through specific signaling pathways have been identified as critical mechanisms underlying the anti-inflammation activity of SSs. In 1975, Yamamoto et al. employed female albino rats to investigate the anti-inflammatory activity of SSs mixture isolated from RB for the first time and found that both intramuscular and oral administration of SSs (SSa and SSd, but not SSc) significantly alleviate the chronic inflammation induced by granuloma pouch and cotton pellets models ([@bib0151]). As two of the major compounds in SSs, SSa and SSd, have been well characterized to inhibit pro-inflammatory cytokines expression. *In vitro* studies indicated that SSa inhibits the expression of pro-inflammatory cytokines, including tumor necrosis factor (TNFα), IL-6 and IL-1β, and increases the expression of anti-inflammatory cytokines, IL-10, in lipopolysaccharide (LPS)-treated macrophages RAW 264.7 cells ([@bib0174]). SSa also inhibits IL-1β-induced inflammatory responses in osteoarthritis chondrocytes by activating LXRα signaling ([@bib0032]), and inhibits LPS-induced production of reactive oxygen species (ROS), TNFα and IL-8 through the suppression of LPS-induced toll-like receptor 4 (TLR4) activation ([@bib0030]). In LPS-induced acute lung injury mice model, SSa reduced pathological injury via inhibiting TNFα and IL-1β and suppressing the NLR family pyrin domain containing 3 (NLRP3) inflammasome function ([@bib0025]). Previous studies also demonstrated that SSa protects rats from carbon tetrachloride (CCl~4~)-induced liver injury and controls cortical impact-induced traumatic brain injury by suppressing hepatic inflammation and neural inflammation, respectively ([@bib0099], [@bib0142]). For the studies on SSd, it has been reported that SSd attenuates pro-inflammatory cytokines expression in RAW 264.7 cells as well as in two different murine models of acute inflammation, carrageenan-induced paw edema in rats and acetic acid-induced vascular permeability in mice ([@bib0090]). SSd also induces the expression of IL-10, an anti-inflammatory cytokine and further protects acetaminophen (APAP)-induced hepatic inflammation and liver injury ([@bib0083], [@bib0090]).

In addition to pro-inflammatory cytokines, numerous inflammatory mediators, including inducible nitric-oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and its enzymatic product, prostaglandins, are characterized as strong promoters for inflammation and inflammatory cells proliferation ([@bib0085]). Previous studies indicated that different purified SSs show diverse effects on COX-2 expression and prostaglandin E2 (PGE2) production. A mixture of SSa, SSc and SSd, of which ratio is the same as in the crude SSs isolated from RB, shows significant inhibitory effects on the production of PGE2 ([@bib0102]). In addition, metabolite profiling evidence suggested that, in formalin-induced acute inflammatory mouse model, SSs (a mixture of SSa, SSb2, SSc, SSd) regulate the metabolism of nicotinate and nicotinamide, which implicate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling via SIRT1 activation, and affect arachidonic acid metabolism to further inhibit PGE2 production ([@bib0095]). In rat peritoneal macrophages, SSa and SSc significantly inhibited the synthesis of PGE2 and the release of arachidonic acid, but SSb1, SSb2 and SSd enhanced the PGE2 production ([@bib0102]). In support of this finding, another study similarly showed that, in rat glioma cells, SSb1 and SSd stimulate the release of PGE2 in a dose-dependent manner ([@bib0059]). However, a recent research demonstrated that SSd inhibits the expression of iNOS and COX-2 in LPS-induced RAW264.7 cells ([@bib0090]) Moreover, saikogenin D, a aglycone of SSd, inhibits the Ca^2+^ ionophore or histamine-induced release of PEG2, but does not affect the basal levels of PEG2 or the conversion of arachidonic acid into PGE2 in C6 rat glioma cells ([@bib0057]). These studies indicate a complicate role of SSs in PGE2 release as well as the regulation of inflammatory responses.

It has been well established that NF-κB is essential for the regulation of inflammation and immune response, and is a key transcription factor involved in the regulation of various inflammatory mediators and pro-inflammatory cytokines ([@bib0003]). Emerging evidence suggested that inhibition of NF-κB signaling pathway plays a central role in the anti-inflammatory effects of SSs. SSa has been found to inhibit the activation of NF-κB signaling pathways in LPS-treated macrophages via suppressing the phosphorylation of inhibitory NF-κB inhibitor α (IκBα) and translocation of p65 NF-κB from cytoplasm to nucleus ([@bib0090], [@bib0174]). A previous study also indicated that SSa protects against experimental sepsis through inhibition of NOD-2/NF-κB and reduction of pro-inflammatory cytokines production ([@bib0167]). Both SSa and SSd play inhibitory roles on the phosphorylation of extracellular matrix-regulated kinase 1/2 (ERK-1/2), p38 mitogen-activated protein kinase (MAPK) ([@bib0172]), c-Jun N-terminal kinase (c-JNK) ([@bib0174]), and other downstream kinases of MAPK pathways, which may synergize with NF-κB signaling pathways and eventually regulate the expression of cytokines, iNOS and COX-2. Modulation of MAPK pathways by SSa and SSd also suppresses oxidized low-density lipoprotein-mediated inflammation and apoptosis of human umbilical vein endothelial cells and thus improves atherosclerosis ([@bib0153]).

Effects of SSs on immune regulation {#sec0007}
-----------------------------------

In addition to the regulative effects on the expression of pro-inflammatory mediators, SSs exert immunoregulatory effects via modulating different types of immune cells, especially T lymphocytes according to several recent studies. A mixture of SSs, including SSa, SSb and SSd, alleviated concanavalin A (con-A)-induced immune hepatic injury by increasing the ratio of CD4^+^/CD8^+^ T cells, enhancing IL-10 expression and inhibiting the production of TNF-α and IL-18 ([@bib0149]). Furthermore, a recent study suggested that, SSa, SSb and SSd regulate immune response and T helper (Th) 1/Th2 cells ratio, associated with increased production of immunosuppressive mediators, including IL-4 and IL-10, and decreased expression of pro-immune mediators, such as IFN-γ and TNF-α in splenocytes ([@bib0132]). Similarly, it has been reported that SSa significantly inhibits the activation/proliferation of T cells and con-A-stimulated production of IL-2, IFN-γ and TNF-α, further leads to cell cycle arrest at G0/G1 phase and apoptosis of T cells by inhibition of the expression of CDK6 and cyclin D3 and upregulation of p27^kip^ levels ([@bib0117]). Recently, Huang et al. reported that SSa induces the activation of WNT/β-catenin pathway and the expression of T-cell factor-1 and lymphoid enhancer factor-1 to promote the osteogenic differentiation of bone marrow stromal cells, which may indirectly modulate the formation of hematopoietic stem cells ([@bib0043]).

Emerging evidence suggested that SSd has similar immunoregulatory effects on the proliferation and activation of T cells. It has been reported that low concentration of SSd bidirectionally regulates T lymphocytes activation, promotes T cells growth responding to suboptimal stimuli, however, represses T cells proliferation upon superoptimal stimuli ([@bib0051]). Recent studies also demonstrated that SSd suppresses different T-cell activators (OKT3/CD28, PMA and con-A)-induced proliferation of human/mouse T cells, inhibits membrane translocation of PKCθ and nuclear translocation of NF-AT and activator protein 1 (AP-1), suppresses IKK- and AKT-induced downregulation of NF-κB signaling pathway, and inhibits IL-2 production ([@bib0050], [@bib0063], [@bib0140]). SSd also inhibits the activation and infiltration of T lymphocytes through suppressing NF-κB, NF-AT and AP-1 signaling to abrogate T cells-derived and TNF-α-induced invasive growth of cancer cells ([@bib0141]). Furthermore, previous study showed that in Anti-Thy1 mAb 1-22-3-induced rat model of glomerulonephritis, SSd significantly reduces the proliferation and infiltration of CD8^+^ T cells, increases expression of anti-inflammatory cytokines IL-10, inhibits the expression of transforming growth factor beta 1 (TGF-β1), and eventually improves inflammation and fibrosis ([@bib0068]). In addition to the regulation of T lymphocytes, SSd has also been found to reduce the differentiation of human monocytes-derived dendritic cells (DCs), promote the DC maturation and enhance the function of mature DCs, and thus was considered as a potential therapeutic candidate for condylomata acuminata ([@bib0156]).

Allergy is acquired hypersensitivity reaction of immune response. IgE-mediated mast cells activation is the central event of allergy. Previous study demonstrated that SSa at lower dose (1 mg/kg) significantly suppresses passive cutaneous anaphylaxis in rats. SSa at higher dose (10  mg/kg) also inhibits allergic asthma in sensitized guinea pigs. Inhibition of allergic mediators' secretion and blockage of histamine-induced effects are potential mechanisms ([@bib0105]). In addition, a recent study suggested that SSa suppresses IgE independent pseudo-allergic reactions induced by compound 48/80 by reducing calcium influx and degranulation of human mast cells (LAD2 cells) through Mrgprx2 (Mas-related genes) pathway ([@bib0133]). Hao et al. also reported that SSd inhibits β-conglycinin (critical mediator of soybean allergy)-induced activation of rat mast cells through suppression of calcium mobilization, ROS production and other signaling transduction, including Cdc42 and c-Fos activation ([@bib0034]). A recent study further identified SSb as a specific agonist of human TAS2R14, a bitter taste receptor, which has drawn great interest because of its bronchodilator and anti-inflammatory effects. Activation of TAS2R14 by SSb then inhibited IgE-induced degranulation of mast cells ([@bib0166]).

Anti-viral activity of SSs {#sec0008}
--------------------------

RB containing TCM formulas, including *Xiao-Chai-Hu-Tang*, are widely used to treat viral respiratory infections caused by respiratory syncytial virus, including influenza virus, parainfluenza viruses, coronaviruses, adenoviruses and rhinovirus in China and eastern Asia. Although anti-HIV, anti-Coxsackie B virus type 1 activities of *Xiao-Chai-Hu-Tang* were reported, whether SSs monomers exhibit similar activities remains elusive ([@bib0010], [@bib0022], [@bib0106], [@bib0144]).

Interestingly, studies focusing on SSs monomers suggested that SSa decreases the replication and infection of several influenza A virus strains, including highly pathogenic H5N1 strain both *in vitro* and *in vivo*, via downregulation of NF-κB and caspase 3-dependent pathways, leads to attenuation of pro-inflammatory cytokines production and selective reduction of lung neutrophil and monocyte recruitment and eventually improves lung injury ([@bib0013]). Cheng et al. further reported that SSb2 inhibits human coronavirus 229E infection *in vitro* at low dose (IC50 around 1.7 µM), probably by interrupting absorption and penetration of the virus without showing cytotoxic effects at the early stage of viral replication, and possesses most potent anti-coronaviral activity than other SSs ([@bib0021]). In addition, a previous study reported that SSd directly inhibits the replication of both measles virus and herpes simplex virus, and has no effect on the growth of infected cells ([@bib0127]).

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are closely related with the development of hepatocellular carcinoma and cirrhosis, and therefore, pose a major threat to human health worldwide. In the past decades, new therapeutic drugs for HBV/HCV have attracted a great deal of attention and are urgently needed. Previous studies demonstrated that *Xiao-Chai-Hu-Tang* exhibits direct anti-hepatitis B virus activities in HBV producing cell lines and potential synergistic effects on vaccine therapy in an HBV carrying murine model ([@bib0004], [@bib0011]). Clinical researches also indicated that *Xiao-Chai-Hu-Tang* promotes HBeAg clearance in patients with chronic HBV infection ([@bib0048], [@bib0120]), and improves liver pathology in patients with HCV who are not candidates for interferon-based treatment ([@bib0024]). The anti-hepatitis virus activities of purified SSs have been well described ([@bib0108], [@bib0138]). A previous study reported that SSc inhibits HBV-DNA replication and HBsAg secretion, without inhibition of cell proliferation, and is even more effective than a well-known antiviral drug, lamivudine ([@bib0023]). A recent study also compared the effects of different SSs on HCV infection and demonstrated that SSb2 acts as a novel efficient inhibitor targeting early HCV entry, neutralizes virus particles, prevents viral attachment, inhibits viral fusion, and blocks HCV infection of primary human hepatocytes ([@bib0077]).

Effects of SSs on oxidative stress {#sec0009}
----------------------------------

The pivotal roles of oxidative stress in the development of aging, cancer, autoimmune disorders, cardiovascular diseases, rheumatoid arthritis, neurodegenerative diseases, and drug-induced liver and kidney injury have been well established. Several studies demonstrated that RB containing herbal formulas, including *Da-Chai-Hu-Tang, Xiao-Chai-Hu-Tang* and *Chai-Hu-Shu-Gan-San*, improve oxidative stress in various animal models, including depressive model, atherosclerosis, nephropathy of diabetes and chemical-induced liver injury ([@bib0044], [@bib0075], [@bib0101], [@bib0113]). In line with these findings, purified SS monomers-based studies suggested that both SSa and SSd reverse impaired hepatic activity of superoxide dismutase, improve hepatic antioxidant defense capability, eliminate of ROS, inhibit lipid peroxidation and eventually protect hepatocytes from chloroform- and CCl~4~-induced oxidative stress and liver injury ([@bib0027], [@bib0142]). These findings were further confirmed by a most recent study showing that SSd significantly protects hepatocyte cell line HL-7702 cells against CCl~4~-induced massive oxidative stress and further inhibits NLRP3 inflammasome-mediated inflammation ([@bib0076]). Similarly, SSd reduced heat stress- and high glucose stress-induced oxidative stress in renal tubular cell lines at least partially through SIRT3-dependent regulation of antioxidant enzyme expression/activity and inhibition of ROS production ([@bib0165], [@bib0168]). SSd also protected cisplatin-induced nephrotoxicity by repressing ROS accumulation and ROS-induced MAPK/NF-κB pathways ([@bib0094]). In addition, SSd exhibited neuroprotective effects on H~2~O~2~-induced oxidative damage in PC-12 cells and MPP^+^-induced oxidative stress and cytotoxicity in SHY5Y cells through inhibition of MAPK signaling and SIRT3 induction, respectively ([@bib0081], [@bib0152], [@bib0163]). Furthermore, SSd alleviated oxidative stress and following cell apoptosis and thus protected against ventilator-induced lung injury ([@bib0131]). On the contrary, according to a recent study, both SSa and SSd sensitized several cancer cell lines to cisplatin treatment by aggravating ROS production and oxidative stress ([@bib0135]). Our previous study also demonstrated that administration of relative high dose of SSs mixture induces oxidative stress in mice, indicated by upregulated lipid peroxidation and repressed hepatic anti-oxidant reactions, and eventually leads to acute liver injury ([@bib0070]). These contradicting findings suggested that effects of SSs on oxidative stress may be cell-type specific and dose dependent.

Effects of SSs on cancers {#sec0010}
-------------------------

The anti-cancer effects of SSs have been extensively studied. Recently, Li and colleagues systemically evaluated the cytotoxicity of SSs and derivatives on different cancer cell lines. SSa, SSd, 6″-O-acetylsaikosaponin-d and 23‑hydroxy‑13β, 28β-epoxy-olean-11-ene-16-one-3-O-β-d-glu-copyranosyl-(1→3)-β-d-fucopyranoside exhibit more potent cytotoxicity than other SS derivatives, and are even more cytotoxic against human hepatoma HepG2 cells and human lung cancer A549 cells than the positive control, 5-fluorouracil ([@bib0065]). A recent study suggested that human colon cancer cells, but not lung cancer, breast cancer and leukemia cells, are sensitive to SSa-induced apoptosis ([@bib0049]). Caspase-4 and downstream sequential caspase-2/caspase-8 activation is suggested to be essential for anti-cancer effects of SSa on human colon cancer cell lines ([@bib0049], [@bib0054]). Several studies further suggested that SSa induces apoptosis in human breast MDA-MB-231 and MCF-7 cells via p53/p21 independent and dependent mechanisms respectively and inhibits the growth of HepG2 by induction of CDK inhibitors ([@bib0014], [@bib0143]). It has also been reported that SSb2 at relative high concentration induces cell cycle arrest at G1 phase and apoptosis through a plausible PKC pathway in B16 melanoma cell lines ([@bib0176]). Long-term treatment of SSb2 at lower concentration induces differentiation of B16 melanoma cells and inhibited melanogenesis without inhibition of cell proliferation ([@bib0175]).

Previous studies demonstrated that SSd induces cleavage of poly-ADP-ribose-polymerase (PARP) via the activation of caspases 3 and 7 ([@bib0023]), inhibits the activation of signal transducer and activator of transcription 3 (STAT3), hypoxia-inducible factor-1α (HIF-1α) and COX-2 induction ([@bib0036]), and further induces cell apoptosis in human hepatocellular carcinoma cells. SSd has also been found to inhibit cell growth of human lung cancer A549 cells and human hepatoma HepG2 and Hep3B cells by induction of p53/p21-mediated G1 phase cell cycle arrest and activation of Fas/FasL apoptotic signaling pathway ([@bib0039]). Recent studies further demonstrated that downregulation of CDK2/cyclin D1 and P53/P21-mediated cell cycle arrest at G0/G1 phase decrease the potential of mitochondrial membrane, and release of cytochrome c are critical for SSd-induced inhibition of human prostate cancer Du145 cells growth and apoptosis of human undifferentiated thyroid carcinoma cells ([@bib0154], [@bib0086]). Several studies also indicated that SSd mediates the apoptosis of human colon cancer HT29 cells via regulation of TRAIL, TRAIL-R, caspase-10 and caspase-8 signaling ([@bib0091]). In addition to direct cytotoxicity to cancer cells, SSd enhanced sensitivity of chemo- or radiation-resistant cancer cells to ordinary anti-cancer therapies. A precious study demonstrated that SSd facilitates mitochondrial fission and cell cycle arrest at G2/M phase through modulating calcium mobilization and further sensitizes chemoresistant ovarian cancer cells to cisplatin-induced apoptosis ([@bib0124]). Recently, it has been reported that SSd increased the radiosensitivity of human hepatoma cells through adjusting G0/G1 checkpoints, and inhibiting expression of HIF-1α under hypoxia conditions ([@bib0129], [@bib0130]). Additionally, both SSa and SSd induce ROS production and oxidative stress, and sensitize different cancer cells, including cervical cancer cell lines and ovarian cancer cell lines, to cisplatin, via activation of caspase pathways ([@bib0134]). Interestingly, a SS-like compound corchorusin-D also activates caspase-9, caspase-3 and PARP cleavage, causes cell cycle arrest at G0 phase and further exhibits anti-leukemic activity ([@bib0098]).

In addition to direct effects on cell cycle arrest and apoptosis, it is noteworthy that SSd inhibits migration, invasion and cancer stem cells expansion of prostate cancers, reverses the epithelial-mesenchymal transition (EMT) and suppresses the expression of metalloproteinase (MMP)−2/9 via blocking Wnt/β-catenin signaling pathway ([@bib0171]). A recent study suggested that SSd acts as a SERCA inhibitor which disturbs intracellular calcium homeostasis, induces endoplasmic reticulum (ER) stress and autophagic cell death *via* CaMKK-mTOR pathway in apoptosis-defective cancer cells, including MCF-7 cells ([@bib0139]). Several *in vivo* studies also suggested that SSd administration in diethylnitrosamine-induced hepatocellular carcinoma (HCC) rat model significantly suppresses inflammation, fibrosis and eventually prevents carcinogenesis through inhibition of COX-2, CCAAT/enhancer binding protein β (C/EBPβ), syndecan-2 and MMPs ([@bib0046], [@bib0092]).

Emerging evidence demonstrated that SS can effectively reverse multidrug resistance and sensitize cancer cells to conventional chemotherapy and radiotherapy. It is well known that over-expression of P-glycoprotein 1 (P-gp) is closely associated with the progression of multidrug resistance during chemotherapy. SSa has been shown to reduce the expression of P-gp and further sensitize cancer cells to various chemotherapy drugs, including doxorubicin, vincristine and paclitaxel, in HepG2 cells and MCF-7 cells ([@bib0155]). Notably, Li et al. reported that SSd increases adriamycin-induced cytotoxicity, downregulates the expression of P-gp and inhibits P-gp-mediated drug efflux in MCF-7 cells *in vitro* as well as in xenograft mice models ([@bib0029], [@bib0064]). Furthermore, through modulating activities of drug transporters, including P-gp, MRP-1, MRP2 and OCT, SSa, SSc and SSd are able to enhance liver-targeting effects of anticancer drugs ([@bib0029]).

Effects of SSs on central nervous system (CNS) {#sec0011}
----------------------------------------------

Various studies recorded that SSs have neuroprotective effects on CNS system and are used to treat depressive-like disorders. Total SSs extracted from RB can reverse the chronic mild stress-induced diminished expression of monoamine neurotransmitter concentrations (5-HT, DA and NE) in the prefrontal cortex ([@bib0116]). Similarly, Sunoh et al. found that RB extract significantly reduces the total duration of immobility in a tail suspension test and exerted an antidepressant activity in mouse model ([@bib0058]). A recent study further confirmed that 4-week administration of SSa attenuates perimenopausal depression-like symptoms induced by chronic unpredictable mild stress by restoring the dysregulation of hypothalamic-pituitary-adrenal (HPA) axis, reducing neuroinflammation and promoting brain-derived neurotrophic factor (BDNF)-TrkB signaling in the hippocampus ([@bib0019]). Like SSa, SSd exerts anti-depressive effects on chronic unpredictable mild stress rats by lowering serum corticosterone levels, alleviating glucocorticoid receptor (GR) suppression and promoting neuron regeneration ([@bib0066]).

SSa also exerts anti-epileptic activity by inhibiting the current of N-methyl-D-aspartic acid (NMDA) and persistent sodium ([@bib0161]) and suppressing epileptiform discharges frequency and increasing the K^+^ current ([@bib0145]). Furthermore, several studies showed that SSa alleviates the chronic constriction injury (CCI)-induced neuropathic pain ([@bib0173]) and eliminates the traumatic brain injury-induced neurological function deficits ([@bib0099]) through inhibiting inflammatory factors and reducing P38 MAPK and NF-κB signaling pathway. Moreover, SSa reduces morphine-maintained responding ([@bib0158]), and cocaine self-administration ([@bib0097]) by activating c-aminobutyric acid (GABA) receptor B.

Oxidative stress plays a critical role in neuronal injury and is closely related with various neurodegenerative diseases ([@bib0037]). SSd has also been found to significantly mitigate the H~2~O~2~-induced apoptosis by reducing the activation of caspase-3 and the cleavage of poly ADP-ribose polymerase (PARP), releasing of malonic dialdehyde (MDA) and lactate dehydrogenase, and by increasing the activity of superoxide dismutase (SOD) via MAPK signaling pathways ([@bib0081]). In addition, SSd acts as GR agonist, regulates mitochondrial function and inhibits the translocation of GR to the mitochondria in cortisone-challenged PC-12 cells, accompanied with upregulation of anti-apoptotic signaling ([@bib0073]).

Another not well studied SS monomer, SSc has recently been documented as a potential dual-target anti-Alzheimer agent due to its effects on Aβ peptides secretion, tau protein function and the expression of synaptic marker proteins such as synaptophysin and PSD-95 ([@bib0062]).

Other hepatoprotective effects {#sec0012}
------------------------------

In addition to reducing oxidative stress in hepatocytes and inhibiting hepatic inflammation during liver injury, SS exerts hepatoprotective effects by regulating the activity of glucose-6-phosphatase, NADPH-cytochrome C reductase and 5′-nucleotidase ([@bib0001]). Both SSa and SSd induce hepatic stellate cells (HSC) cell lines apoptosis through caspase pathways even at relatively low concentration ([@bib0012], [@bib0017]). Previous studies also showed that SSa and SSd directly decrease the expression and phosphorylation of ERK1/2 to modulate inflammation in HSCs and further inhibit HSCs activation and then liver fibrosis ([@bib0016]). Bone morphogenetic protein 4 (BMP-4), a member of TGF-beta superfamily which is elevated in bile duct legation or cancer livers, is able to stimulate the α-smooth muscle alpha actin (α-SMA) levels in HSCs and enhance TGF-β-induced EMT ([@bib0028]). It is noteworthy that SSa also directly inhibits the HSC activation by downregulating the expression of BMP-4 and α-SMA ([@bib0137]). Intriguingly, a most recent study suggested that SSd and estradiol suppress oxidative stress-induced extracellular matrix deposition by rat HSC-T6 cells through an estrogen receptor dependent pathway ([@bib0110]).

Toxicity of SSs {#sec0013}
===============

To date, although RB extract and RB containing TCM formulas are widely used for the treatment of various diseases, including chronic hepatic inflammation and viral hepatitis, overdose-induced acute or accumulation-related chronic hepatotoxicity and other digestive system diseases have also been documented ([@bib0009], [@bib0134]). According to clinical observations, patients who use *Xiao-Chai-Hu-Tang* or other traditional Chinese prescriptions containing more than 19 g of RB have a higher risk of liver diseases ([@bib0060]). Meanwhile, Japanese researchers also reported that long-term oral administration of *Xiao-Chai-Hu-Tang* causes cholestatic liver injury, interstitial pneumonia and even death ([@bib0045], [@bib0164]).

Our previous study suggested that SSs time- and dose-dependently activates oxidative stress and induces liver injury, indicated by increased serum transaminase activities and liver SOD activity, and upregulated content of MDA in both mice and rats ([@bib0093], [@bib0134], [@bib0042]). We also reported that SSd inhibits cell viability, decreases mitochondrial membrane potential and stimulates apoptosis *via* caspase and platelet-derived growth factor-β receptor/p38 signaling pathways in hepatocytes ([@bib0015]). To further determine the role of SSs in liver injury, a proteomic technology, iTRAQ labeling coupled with LC-MS/MS, was employed to reveal time- and dose-related patterns of SS-induced acute hepatotoxicity and downstream regulated targets or signaling pathways ([@bib0070]). According to proteomic results, SS administration induced the change of 487 differentially expressed proteins and upregulated the expression of several proteins involved in lipid metabolism, protein metabolism, macro molecular transportation, cytoskeleton structure and response to stress ([@bib0070]). Among the altered proteins, cytochrome P (CYP) 2E1 is markedly and rapidly upregulated after SS administration, accompanied with increased ROS production and oxidative stress in a time- and dose-dependent manner. Fatty acid oxidation processes are also significantly disrupted, indicated by dysregulation of related proteins expression. These findings are consistent with previous studies and suggest a potential mechanism of SS-induced liver injury. Interestingly, only the dose higher than 12.957  mg/kg (8-fold higher than clinical safety dose of SSs) induces acute liver injury in animals, indicating that SS-induced pharmacological and toxicological effects are dosage related. Furthermore, comparative toxicology analysis suggested that the SSs-altered proteins in acute liver injury highly overlapped with the altered proteins in acute kidney injury, suggesting potential risk of high dose SSs-induced nephrotoxicity.

Metabolism of SSs {#sec0014}
=================

Although SS containing prescriptions are widely clinical practiced, metabolism of SS, especially in human, is not extensively studied. Recent studies regarding to the metabolism of SSs are summarized in [Fig. 3](#fig0003){ref-type="fig"} . In TCM, most of the herbal drugs are administrated orally, so that biotransformation of bioactive compounds in gastric acids and intestinal microflora are unneglectable for the research of drug metabolism. In late 1990s, several *in vitro* and *in vivo* studies demonstrated that in gastric acid, SSa completely, yet slowly (over 3 h) transformed into SSb1 and SSg in a ratio of 3:1; SSd rapidly and completely changed into SSb2 in about 30 min, which is similar to the transformation of SSs in VBRB ([@bib0112]). Further, rat or human intestinal microflora or bacteria with hydrolyzing activity, like *Eubacterium* sp. A-44, induces the deglycosylation of SS, from SSa, SSb1, SSb2, SSc, SSd and SSg into prosaikogenin (PSG) F, A, D, E, G and H, and corresponding saikogenin (SG) F, A, D, E, G and H, respectively ([@bib0053], [@bib0112], [@bib0159]). Hydrolyzation of β-glucosidic bond and β-fucosidic bond are required for PSG and SG formation, respectively ([@bib0052]). Previous studies suggested that SSs are hard to be absorbed through intestinal membrane. However, owning to significant improvement of detection sensitivity using LC-MS/MS, Xu et al. demonstrated that SSa, SSc and SSd are rapidly absorbed into blood within 30 min at very low concentration (about 50  ng/ml for SSa, and 20  ng/ml for SSc and SSd in the plasma, 30 min after oral administration of RB extract with dose of 17.5  g raw RB/kg in rat, equals to about 41.8  mg/kg SSa, 9.7  mg/kg SSc and 18.6  mg/kg SSd) ([@bib0147]). PSGs and SGs are considered to be more permeable when compared to SSs and can be more easily absorbed though intestine membrane. Higher concentration of SS metabolites in human plasma when compared to rat plasma is expected, since the hydrolysis of SS is much faster when SSs are incubated with human intestinal bacteria ([@bib0122]). Intravenous administration of RB extracts, which is approved by CFDA for the treatment of fever, leads to direct distribution of SSs in all organs, especially in the liver through circulation, with a t~1/2~ of about 30 min ([@bib0084], [@bib0121]).Fig. 3Diagram for SSs metabolism pathways. Different weight of lines indicates abundance of products.Fig 3

In addition to deglycosylation, other metabolism routes are also important for SSs *in vivo* transformation, supported by an *in vivo* study which indicates that after oral administration of SSa, total recovery of SSa, PSGF and SGF is only about 50% of starting dose ([@bib0112]). A recent study further identified 15 new metabolites of SSa, in addition to PSGF and SGF, after oral or intravenous administration, which are products of hydration and monooxidation on the aglycone moiety and β-glucosidic bond hydrolyzation in the liver, and metabolites of PSGF and SGF after dehydrogenation, hydroxylation and carboxylation. The metabolic routes are different depends on different administrative routes ([@bib0084]). The same research group also confirmed that, similar to SSa, SSd and its derivatives PSGG and SGG are all transformed into phase-1 metabolites through liver microsome- and CYP enzymes-mediated oxidation, including dehydrogenation, monooxidation, and carboxylation and combination of these processes on aglycone moiety ([@bib0160]).

Discussion and perspectives {#sec0015}
===========================

RB containing TCM formulas have been widely used clinically in China and eastern Asia, and SSs are believed to be the major bioactive compounds in RB and contributes to anti-inflammation, anti-viral and hepatoprotective effects of RB and RB-containing TCM formulas. Hence, the pharmacological and toxic effects of SSs have been extensively studied. Anti-inflammation, anti-viral and immunoregulation effects of SSs at relatively low concentration (about 10 µM) are most promising, so that SSs can be considered as potential therapeutic options for the treatment of diseases in which inflammation is major driving factor, including but not limit to respiratory system infectious diseases, viral hepatitis, fatty liver diseases, liver fibrosis and atherosclerosis. Most of the anti-inflammatory and immune regulation studies were mainly focused on SSa, SSb2 and SSd. Among them, SSa seems to be more potency on the inhibition of cytokines expression; SSd is more effective on immune suppression; and SSb2 is mostly exhibiting anti-viral activities. High concentration of SSa and SSd (50 µM), however, stimulate inflammation by promoting PGE2 secretion in rat glioma cells, which is highly plausible response of these cells to high concentration of SSs-induced excessive cell death. In addition, the effects of SSs and RB-containing TCM on CNS system, especially on depression, have drawn great attentions over the past decades. Combination of anti-inflammatory effects and direct effects on behavior regulation of hippocampal neuron cells has been identified as critical mechanism. But, the direct target of SSs in the CNS system is still unknown.

Experimental evidence can sometimes be contradictory, when it comes to anti-cancer, anti-oxidant and anti-apoptosis effects of SSs. In several kidney epithelial cell lines and neuron related cell lines, SSd exhibits anti-oxidant and further anti-apoptotic effects against challenges under certain conditions, including H~2~O~2~, heat stress and high glucose at very high concentration (from 30 µM to 150 µM). On the contrary, we reported that SSs at high concentration induce oxidative stress and further apoptosis in the liver or hepatocytes through interruption of lipid oxidation ([@bib0070]). In addition, as low as 2 to 10 µM of SSa and SSd are able to sensitize several cancer cell lines, including Hela, Siha, A549 and SKOV3 cells to cisplatin-induced cell death by induction of ROS accumulation and oxidative stress. SSa, SSb2 and SSd around 2 to 20 µM also exert cytotoxicity in cancer cell lines by inducing cell cycle arrest and further activation of caspase and mitochondrial-dependent cell apoptosis. What is more confusing is that SSa and SSd at as low as from 1 to 10 µM can induce apoptosis in HSCs and fibroblast cell lines, which is believed to contribute to anti-fibrotic effects of SSs against CCl~4~-induced liver injury. However, at the same time, SSa and SSd inhibit CCl~4~-mediated oxidative stress and apoptosis in hepatocytes and thus alleviate CCl~4~-induced liver fibrosis. Although these contradictory results can be partially explained by cell type-specific metabolism status, basal levels of ROS and tolerance to oxidative stress, further studies are urgently required to address these concerns.

Some potential pharmacological effects of SSs are still not well characterized. Previous researches in 1970s reported serum cholesterol lowering effect of SSs in rat ([@bib0150]). A recent study also suggested that VBRB regulates lipid disorders in high-fat-diet-induced obese rats ([@bib0126]). However, no further researches support these findings. Our recent proteomic study of SSs mixture suggested that relative low dose of SSs mixture significantly regulate lipid transportation through upregulation of protein levels of ApoA 1, 2, 4, and 5, which are all critical for lipoprotein assembly and lipid transportation ([@bib0070]). Proteins primarily involved in triglyceride hydrolyzation, intracellular fatty acid transportation and fatty acid oxidation pathways are also significantly upregulated by SS mixture ([@bib0070]). These findings indicate that SSs may have significant effects on lipid homeostasis in livers and lipid transportation between vital organs. More experimental evidence is still required to confirm these preliminary data from our proteomic study.

The lack of sufficient understanding regarding to the metabolism of SSs contributes to significant pitfall for the pharmacology and toxicology studies, especially *in vivo* studies. It is noteworthy that after oral administration of SSs extract, the most common administrative way for RB containing TCM, three major components, SSa, SSc and SSd can only be found in plasma at concentrations of around 60 nM, which is about 100- to 1000-fold lower than the concentration used for current *in vitro* studies. Thus, the biological relevance of all current studies, which are using extensively high dosage of SSs, are vulnerable. In addition, low pH condition, including gastric acids or vinegar baking in TCM processing (VBRB), contributes to transformation of SSs, mainly from SSa to SSb1 and SSd to SSb2. Although it is believed that VBRB, in which most of the SSd is transformed to SSb2, is more effective and safer to treat liver diseases, experimental evidence regarding hepatoprotective effects of SSb2, except anti-viral effects, is still missing. Furthermore, after oral administration, intestinal bacterial environment results in bio-transformation of SSs into PSGs and SGs, which can be further metabolized into other derivatives. However, barely no pharmacological study is focusing on these metabolic products of SSs. Therefore, systemic evaluation of PSG, SG and SSs metabolites for their pharmacological and toxic effects is necessary and will be not only vital for the understanding of therapeutic potency of SSs, but also crucial for the discovery of SS derivatives as novel drug candidates. Furthermore, based on current knowledge, dosage is the primary risk factor for toxicity of SSs administration. Identification and characterization of *in vivo* pharmacokinetic property of SSs will not only benefit the discovery of SSs based therapeutic strategy, but also provide experimental evidence for the safety clinical use of RB containing TCM, since SSs are the primary bioactive and quality control substances in RB.

To further improve drug-like properties, including solubility, absorbance, other pharmacokinetic properties and bioactivities of SSs and derivatives by chemical structural modification, it is essential to identify *in vivo* target, interactive patterns and structure-activity relationship of SSs and derivatives. As summarized in [Fig. 2](#fig0002){ref-type="fig"}, numerous studies suggested that NF-κB is the potential target responsible for the anti-inflammatory effects of SSs. Inhibition of NF-κB activation and translocation leads to suppressed transcription of pro-inflammatory cytokines and regulators and at least partially increased anti-inflammatory cytokines expression. However, whether SS directly interact with and inhibit NF-κB or interrupt NF-κB signaling by interacting with other components is still unclear. Emerging evidence also indicated that MAPK pathways are also partially responsible for anti-inflammatory, anti-oxidative and anti-cancer effects of SSs. However, since MAPK pathway is a common cascade signaling transduction pathway shared by various different upstream stimulus, the specificity of the effects of SSs on MAPK pathway is questionable. For the anti-allergic effects of SSs, inhibition of calcium mobilization which results in reduced mast cells activation was found in two independent studies. In addition, a most recent study identified a potential target of SSb for its anti-allergic effects, TAS2R14, by using cell-based functional assay and molecule docking. However, the role of TAS2R14 in inflammation and other diseases is still elusive. For the anti-oxidative effects, several studies suggested that SIRT1 is involved by upregulating endogenous anti-oxidative mechanisms. However, the underlying molecular mechanism is not characterized. For the anti-cancer mechanisms of SSs, conventional apoptotic pathways, including TRAIL pathways, Fas/FasL pathways, caspase pathways and cell cycle arrest, have been documented. The down-regulation of drug resistance proteins, especially P-gp, in cancer cells by SSs has been highlighted by several studies. However, no other specific intracellular target has been identified. Disrupted cancer cell membrane structures induced by detergent property of SSs at high concentration may also contribute to anti-cancer activities of SSs. For the effects of SSs on CNS, primary mechanisms are anti-inflammation, oxidative stress and regulation of neurotransmitter expression. Overall, most of the studies regarding to the bioactivities of SSs, including anti-viral and hepatoprotective activities, are primarily focusing on pharmacodynamics evaluation but not molecular mechanisms and targets identification. With the development of modern biotechnologies, transcriptomic and proteomic studies can be novel approaches to identify SSs- and its derivatives-regulated biological pathways. Employment of iTRAQ-based proteomic analysis successfully identified that SSs modulate several fatty acid oxidation pathways, including peroxisome proliferator-activated receptor pathways and sterol regulatory element-binding proteins pathways and eventually contribute to acute liver injury in our most recent study. Data mining and bioinformatics analysis will provide comprehensive evidence for the identification of possible targets of SSs. Further biological studies are also required to confirm results from transcriptomic and proteomic studies.

Conclusion {#sec0016}
==========

As most characterized bioactive compounds in widely used herbal drug RB, SSs have drawn a great deal of attention over the past several decades because of its potential anti-inflammation, anti-viral, anti-cancer and hepatoprotective effects. Further pharmacokinetic study of SSs administration, systemic evaluation of the bioactivities of SS derivatives and metabolic products, dose-time-pharmacological/ toxic effects relationship and identification of biological targets and interaction patterns are urgently required. These studies are not only vital for the development and discovery of SSs-based drugs and therapeutic strategies, but also important for the clinical safe use and improvement of RB containing TCM formulas.
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